Cardio Diagnostics Holdings, Inc. has announced that it will present new data at the upcoming American Heart Association (AHA) Scientific Sessions in New Orleans, scheduled from November 7 to 10. The data will demonstrate that the company's PrecisionCHD test, an integrated epigenetic-genetic blood test, is able to detect Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA). These are forms of heart disease that are often underdiagnosed by standard testing methods. The results have not yet been presented; they are scheduled for presentation at the AHA Scientific Sessions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardio Diagnostics Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105196979) on November 05, 2025, and is solely responsible for the information contained therein.